Evaluating the ‘real’ cost-effectiveness of health technology: reconciling the public interest with patients’ interests

References

• Hjelmgren J, Berggren F, Andersson F. Health economic guidelines – similarities, differences and some implications. Value Health 2001;4:225–50
   Google Scholar
• Raftery JP. Review of NICE’s recommendations, 1999–2005. BMJ 2006;332:1266–8
   PubMed Web of Science ®Google Scholar
• Dillon A. Letter to manufacturers regarding transfer to STA process. NICE, 29 November 2005 Available at: www.nice.org.uk/download.aspx?o=281942> (last accessed: 25th July 2006)
   Google Scholar
• McEwan P, Poole CD, Tetlow T, et al. Evaluation of the cost effectiveness of insulin glargine versus NPH insulin for the treatment of type 1 diabetes in the UK. Curr Med Res Opin 2007;23(Suppl 1):S17–19
   PubMedGoogle Scholar
• McEwan P, Poole CD, Tetlow T, et al. Evaluation of the cost effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK. Curr Med Res Opin 2007;23(Suppl 1):S21–31
   Google Scholar
• Rothwell PM. External validity of randomised controlled trials: ‘To whom do the results of this trial apply?’ Lancet 2005;365:82–93
   PubMed Web of Science ®Google Scholar
• Currie CJ, Poole CD, Tetlow T, et al. The outcome of care in people with type 1 and type 2 diabetes following switching to treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis. Curr Med Res Opin 2007;23(Suppl 1):S33–39
   Google Scholar
• Poole CD, Tetlow T, McEwan P, et al. The prescription cost of managing people with type 1 and type 2 diabetes following initiation of treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis. Curr Med Res Opin 2007;23(Suppl 1):S41–48
   Google Scholar
• Pieber TR, Treichel HC, Robertson LI, et al. Detemir plus insulin aspart is associated with less risk of major as well as nocturnal hypoglycaemia than insulin glargine plus insulin aspart at comparable levels of glycaemic control in type 1 diabetes. Diabetologia 2005;48(Suppl 1):A92–2
   Google Scholar
• Warren E, Weatherly-Jones E, Chilcott J, et al. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technol Assess 2004;8(45):iii, 1–57
   Google Scholar
• Currie CJ, Morgan CLl, Poole CD, et al. Multivariate models of health related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006;22:1523–34
   PubMed Web of Science ®Google Scholar
• Leese GP, Wang J, Broomhall J, et al. Frequency of severe hypoglycaemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 2003;26:1176–80
   PubMed Web of Science ®Google Scholar
• The DCCT Study Group. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. Am J Med 1991;90:450–9
   PubMed Web of Science ®Google Scholar
• NICE. Guide to the single technology appraisal (STA) process (Interim process). 11 November 2005. Available from: www.nice.org.uk/page.aspx?o=278616 [Last accessed 25 April 2006]
   Google Scholar
• NICE. The guidelines manual – Chapter 7: Reviewing and grading the evidence. London: NICE, 2006
   Google Scholar
• Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ 2001;323:334–6
   PubMed Web of Science ®Google Scholar
• NICE. The guidelines manual – Chapter 8: Incorporating health economics in guidelines and assessing resource impact. London: NICE, 2006
   Google Scholar
• Centre for Reviews and Dissemination, University of York. Available from: www.york.ac.uk/inst/crd [Last accessed: 20 July 2006]
   Google Scholar
• Drummond M, Davies L. Economic analysis alongside clinical trials: revisiting the methodological issues. Int J Technol Assess Health Care 1991;7:561–73
   PubMedGoogle Scholar
• O’Brien B. Economic evaluation of pharmaceuticals: Frankenstein’s monster or vampire of trials. Medical Care 1996;34 (12 Suppl):DS99–108
   Google Scholar
• Braunholtz DA, Edwards SJL, Lilford RJ. Are randomized clinical trials good for us (in the short term)? Evidence for a ‘trial effect.’ J Clin Epidemiol 2001;54:217–24
   Google Scholar
• National Institute for Clinical Excellence. Appraisal Consultation Document: The clinical effectiveness and cost effectiveness of long acting insulin analogues for diabetes. Available at: www.nice.org.uk/page.aspx?o=35497 [Last accessed: 25 October 2005]
   Google Scholar
• Misbin RI. Medical Review of detemir (NDA 021–536). Centre for Drug Evaluation & Research, US Food and Drug Administration. 9th June 2005. <http://www.fda.gov/cder/foi/nda/2005/021�536_levemir_medr.pdf> (last accessed: 20th June 2006)
   Google Scholar
• Insulin detemir (rys) cartridge 3 mL (Penfill ), prefilled device 3 mL (FlexPen), 100 U/mL, Levemir, July 2005. Department of Health and Government, Australia. Available at: www.health.gov.au/internet/wcms/publishing.nsf/Content/pbac-psdinsulind [Last accessed 4 May, 2006]
   Google Scholar
• Russmann A, Schreiber S. Treatment with insulin glargine of patients with type 1 diabetes in clinical practice: metabolic control over 30 months. Diabetologia 2004;47\(Suppl. 1): [Abstract 842]
   Google Scholar
• Schreiber, S, Russmann, A. Treatment with insulin glargine of patients with type 2 diabetes in clinical practice: metabolic control over 30 months. Diabetologia 2004;47(Suppl 1): A271 [Abstract 748]
   Google Scholar
• Winocour PH. Effective diabetes care: a need for realistic targets. BMJ 2002;324:1577–80
   PubMed Web of Science ®Google Scholar
• Fanelli CG, Porcellati F, Pampanelli S, Bolli GB. Insulin therapy and hypoglycemia: the size of the problem. Diabetes Metab Res Rev 2004;20(Suppl 2):S32–42
   PubMedGoogle Scholar
• Insulin Glargine, injection, 100 units per mL, 10 mL vials and 3 mL x 5 cartridges, Lantus®, July 2005. Department of Health and Government, Australia. Available from: www.health.gov.au/internet/wcms/publishing.nsf/Content/pbac-psd-insulin [Last accessed 4 May, 2006]
   Google Scholar